<![CDATA[Pivotal phase 3 trial launches of rinzimetostat plus darolutamide in mCRPC]]>
ORIC Pharmaceuticals, in collaboration with Bayer, has initiated the pivotal phase 3 Himalayas-1 trial evaluating rinzimetostat plus darolutamide (Nubeqa) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed …